Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Gestational diabetes and maternal obesity are associated with epigenome-wide methylation changes in children

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The R213G polymorphism in SOD3 protects against allergic airway inflammation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Experimentally induced testicular dysgenesis syndrome originates in the masculinization programming window

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Muscle-liver substrate fluxes in exercising humans and potential effects on hepatic metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dairy products influence gut hormone secretion and appetite differently: A randomized controlled crossover trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Metformin reduces plasma glucose and has been shown to increase glucagon-like peptide 1 (GLP-1) secretion. Whether this is a direct action of metformin on GLP-1 release, and whether some of the glucose-lowering effect of metformin occurs due to GLP-1 release, is unknown. The current study investigated metformin-induced GLP-1 secretion and its contribution to the overall glucose-lowering effect of metformin and underlying mechanisms in patients with type 2 diabetes.

METHODS: Twelve patients with type 2 diabetes were included in this placebo-controlled, double-blinded study. On 4 separate days, the patients received metformin (1,500 mg) or placebo suspended in a liquid meal, with subsequent i.v. infusion of the GLP-1 receptor antagonist exendin9-39 (Ex9-39) or saline. During 240 minutes, blood was sampled. The direct effect of metformin on GLP-1 secretion was tested ex vivo in human ileal and colonic tissue with and without dorsomorphin-induced inhibiting of the AMPK activity.

RESULTS: Metformin increased postprandial GLP-1 secretion compared with placebo (P = 0.014), and the postprandial glucose excursions were significantly smaller after metformin + saline compared with metformin + Ex9-39 (P = 0.004). Ex vivo metformin acutely increased GLP-1 secretion (colonic tissue, P < 0.01; ileal tissue, P < 0.05), but the effect was abolished by inhibition of AMPK activity.

CONCLUSIONS: Metformin has a direct and AMPK-dependent effect on GLP-1-secreting L cells and increases postprandial GLP-1 secretion, which seems to contribute to metformin's glucose-lowering effect and mode of action.

TRIAL REGISTRATION: NCT02050074 (https://clinicaltrials.gov/ct2/show/NCT02050074).

FUNDING: This study received grants from the A.P. Møller Foundation, the Novo Nordisk Foundation, the Danish Medical Association research grant, the Australian Research Council, the National Health and Medical Research Council, and Pfizer Inc.

OriginalsprogEngelsk
TidsskriftJCI Insight
Vol/bind3
Udgave nummer23
Sider (fra-til)93936
ISSN2379-3708
DOI
StatusUdgivet - 6 dec. 2018

ID: 55793924